Skip to Content

Continuing Education

Navigating the Evolving Multiple Myeloma Treatment Landscape: Bispecifics, CAR-T, & CELMoDs (On-Demand | 2026 NCODA International Fall Summit)

Best Suited For: Pharmacist, Pharmacy Technician, Nurse, Nurse Practitioner, Physician Assistant

CE Credits: 1.0 hour

Activity Description

This activity will review the evolving role of CAR T-cell therapy, bispecific antibodies, and cereblon E3 ligase modulatory drugs (CELMoDs) in multiple myeloma, including their movement into earlier lines of treatment. Through multidisciplinary expert discussion, participants will explore treatment selection and sequencing, recognition and management of treatment-related toxicities, and supportive care considerations. The session will also address operational and workflow considerations for delivering these therapies in community oncology practice. Participants will examine how multidisciplinary team members support safe medication use, patient education, and coordination of care across community and academic settings.

CE Credit: 1.0 hour
Fee: This activity does not require payment to register.

LOGIN TO NCODA CONNECT FOR THIS CE ACTIVITY

Learning Objectives

  1. Review the evolving role of CAR T-cell therapy, bispecific antibodies, and Cereblon E3 Ligase Modulatory Drugs (CELMoDs) in the management of relapsed/refractory multiple myeloma, including considerations for treatment selection and sequencing.
  2. Describe evidence-based strategies for recognizing, grading, and managing treatment-related toxicities associated with CAR T-cell therapy and bispecific antibodies, including cytokine release syndrome (CRS), neurotoxicity (ICANS), and infection risk.
  3. Discuss operational and workflow considerations for implementing bispecific antibody therapy in community oncology practice, including step-up dosing, patient monitoring, interdisciplinary communication, and coordination of care.
  4. Identify the roles of the oncology multidisciplinary team in supporting safe medication-use processes, treatment coordination, and patient education for emerging multiple myeloma therapies.
  5. Summarize practical approaches to optimizing patient outcomes through multidisciplinary management of patients receiving CAR T-cell therapy, bispecific antibodies, and novel CELMoD therapies.

 

Obtaining CE Credit

To claim CE credit, select Complete Credit Requirements in your LecturePanda registration confirmation email and complete all the steps listed below:

  • Review the course learning materials.
  • Confirm the information you provided at registration.
  • If you’re completing an on-demand activity, watch the CE video in full.
  • Enter the CE code shared near the end of the activity.
  • Complete all required evaluations and CE assessments.

All CE credit requirements must be completed by 11/17/2029. Upon completion, eligible continuing education credit will be submitted to the appropriate accrediting body. Pharmacist and pharmacy technician credit will be reported to ACPE and reflected in your CPE Monitor profile within 24 hours. Reporting timelines for other healthcare professions may vary by accrediting body or state board.

CE information for nurses, nurse practitioners (NPs), and physician assistants (PAs) can be found here.